NeoGenomics (NEO)
About
Business overview of NeoGenomics (NEO)
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Key Insights
Critical company metrics and information
Share Price
$18.61Market Cap
$2.39 BillionTotal Outstanding Shares
128.36 Million SharesTotal Employees
2,100Dividend
No dividendIPO Date
January 25, 1996SIC Description
Services-testing LaboratoriesPrimary Exchange
NASDAQType
Common StockPhone Number
(239) 768-0600Address
9490 neogenomics way, Fort myers, FL, 33912Homepage
https://www.neogenomics.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $15.01 Million |
| Net Cash Flow, Continuing | $55.75 Million |
| Net Cash Flow From Financing Activities, Continuing | $5.23 Million |
| Net Cash Flow From Financing Activities | $5.23 Million |
| Net Cash Flow From Investing Activities, Continuing | $35.52 Million |
| Net Cash Flow From Operating Activities | $15.01 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-77.73 Million |
| Income Tax Expense/Benefit | $-2.10 Million |
| Diluted Average Shares | $126.64 Million |
| Net Income/Loss Attributable To Parent | $-77.73 Million |
| Benefits Costs and Expenses | $723.95 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Assets | $1.64 Billion |
| Current Assets | $590.24 Million |
| Liabilities | $732.90 Million |
| Equity Attributable To Parent | $908.21 Million |
| Noncurrent Assets | $1.05 Billion |
| Current Liabilities | $296.41 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.